Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could cannabis calm drug-resistant epilepsy? new trial seeks answers.

NCT ID NCT07023744

Disease control Sponsor: University of Manitoba Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether cannabis-based treatments can safely reduce seizures in people aged 2 to 55 with drug-resistant epilepsy. Participants will receive either a pure CBD extract, a CBD-rich herbal cannabis extract, or a placebo. The goal is to see if these treatments lower monthly seizure counts and improve quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

24 months to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ages 24 months to 55 years old at the time of enrollment 2. Diagnosed with DRE: not achieved seizure freedom, with adequate trials of 2 antiseizure medications 29 3. Medical history of 4 + clinically recognizable seizures (any type with clusters counted as a single event) per month 4. Have a negative pregnancy test at screening for patients who have experienced menarche 5. Agree to abstain from driving and recreational cannabis use throughout the study Exclusion Criteria: 1. Diagnosis of psychogenic non-epileptic seizure 2. Recent (\<30 days) change in anticonvulsant therapies including anticonvulsant medications, or settings on vagal nerve stimulator 3. Ketogenic diet started within 6 months (participants stable on the ketogenic diet for more than 6 months are eligible to participate) 4. Vagal nerve stimulator implanted and activated within 12 months 5. Concomitant regular use of narcotics (except in emergencies and physician supervised) 6. Initiation or dosage change of oral or injected steroids within 3 months 7. Allergy or intolerance to compounds in trial preparations 8. DRE secondary to progressive neurological disease 9. Clinically significant cardiac, renal or hepatic disease (as assessed by site investigator); elevated liver enzymes (GGT and/or AST and/or ALT) or lipase \>3 times upper limit, adjusted for age 10. History of psychotic disorders 11. Uncontrolled (in the perspective of the qualified investigator) medical conditions including substance use disorders 12. History or concurrent cannabis use disorder 13. Unwilling or unable to use highly effective methods of contraception throughout the study period and three months post-trial, where applicable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug resistant epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence Drug Resistant Epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug resistant epilepsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.